AviadoBio Bets on Blood-Brain Barrier Technology in Push for One-Time Alzheimer's Treatment

For a long time - decades - the blood-brain barrier has been one of the most stubborn obstacles in neurology. Protective by design, it blocks the vast majority of therapeutics from reaching the central nervous system, a problem that has frustrated drug developers targeting everything from brain tumours to Alzheimer's disease. A new licensing agreement between Aviado Bio and Apertura Gene Therapy represents the latest attempt to crack this problem, this time by exploiting a well-characterised biological transport mechanism to ferry gene therapy directly into the brain.

Under the deal, London-based AviadoBio has licensed TfR1 CapX™, a next-generation adeno-associated virus (AAV) capsid developed by New York-based Apertura. The capsid is engineered to bind human transferrin receptor 1 (hTfR1), a protein expressed on the surface of brain endothelial cells that naturally shuttles iron-bound transferrin across the blood-brain barrier. By hitching a ride on this established pathway, TfR1 CapX is designed to enable intravenous delivery of genetic payloads to neurons and astrocytes throughout the brain and spinal cord, without the need for invasive surgical administration.

AviadoBio intends to combine TfR1 CapX with its proprietary vMiX™ platform, a vectorised RNA interference system that uses AAV delivery to silence disease-causing genes. Unlike conventional RNAi therapies requiring repeated dosing, vMiX is designed to provide durable gene knockdown from a single administration. The company is applying the platform across a pipeline targeting neurodegenerative diseases, with its most advanced CNS programme being AVB-406, an investigational gene therapy for Alzheimer's disease and related tauopathies, which works by silencing MAPT, the gene encoding tau protein.

Tau accumulation is a defining pathological feature of Alzheimer's and a range of other neurodegenerative conditions collectively known as tauopathies. Reducing tau expression at the genetic level, rather than attempting to clear aggregated protein after the fact, is a mechanistically distinct approach from many of the antibody-based strategies that have dominated the Alzheimer's field in recent years.

Lisa Deschamps, Chief Executive Officer of AviadoBio, said the agreement

and that it:

The choice of TfR1 as a brain shuttle target is not arbitrary. It is among the most extensively characterised CNS delivery receptors in the field, with a track record in clinical contexts spanning paediatric and geriatric populations. Alex Bloom, Chief Technology Officer at AviadoBio, described it as

adding that the licence

Preclinical data shared by both AviadoBio and independent groups suggest TfR1 CapX achieves widespread neuronal and astrocytic transduction across the brain and spinal cord, a meaningful distribution profile for diseases like Alzheimer's that affect broad neural networks rather than discrete anatomical regions. Apertura itself describes TfR1 CapX as a second-generation capsid, demonstrating superior CNS delivery over its predecessor, BI-hTFR1, the first-generation version of which was published in the journal Science.

Dave Greenwald, Managing Director at Deerfield Management and Executive Chairman at Apertura, expressed confidence in the pairing:

That said, AVB-406 remains at the preclinical stage, and the distance from preclinical promise to clinical validation in Alzheimer's disease is well-documented and rarely straightforward. Gene therapy for CNS indications brings its own manufacturing, safety, and immunogenicity considerations, and no AAV-based therapy for Alzheimer's has yet demonstrated clinical efficacy. The field is watching closely, but cautious optimism is warranted rather than anything stronger.

The deal's near-term significance will become clearer in the coming weeks. AviadoBio is scheduled to present three oral presentations on AVB-406 at the American Society of Gene & Cell Therapy Annual Meeting in Boston, taking place 11th - 15th May 2026. The presentations will cover preclinical, translational, and manufacturing data, offering the scientific community its most comprehensive public look yet at a programme that, if the underlying biology holds up, could eventually represent a genuinely novel approach to one of medicine's most intractable diseases.

Whether TfR1 CapX and vMiX together can deliver on their mechanistic rationale remains to be seen. But as delivery technology goes, the combination is scientifically credible, and for a disease that has resisted treatment for so long, credible is a reasonable place to start.